(NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare ...
Background Treatment strategies for Crohn’s disease (CD) suppress diverse inflammatory pathways but many patients remain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback